[{"id":"6b19c0a6-ae66-4201-9c5b-978c28f8c121","acronym":"","url":"https://clinicaltrials.gov/study/NCT04514484","created_at":"2021-01-18T21:38:07.896Z","updated_at":"2025-02-25T16:45:04.992Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","source_id_and_acronym":"NCT04514484","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD276 • VTCN1 • CD4 • HHLA2","pipe":"","alterations":" ","tags":["CD276 • VTCN1 • CD4 • HHLA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 11/02/2025","primary_completion_date":" 11/02/2025","study_txt":" Completion: 11/02/2025","study_completion_date":" 11/02/2025","last_update_posted":"2025-02-05"},{"id":"c354bd79-6619-40c4-8e90-94c882a12503","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958199","created_at":"2023-07-24T15:08:51.673Z","updated_at":"2024-07-02T16:35:06.173Z","phase":"Phase 1","brief_title":"A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7","source_id_and_acronym":"NCT05958199","lead_sponsor":"NextPoint Therapeutics, Inc.","biomarkers":" HHLA2","pipe":"","alterations":" ","tags":["HHLA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPX267"],"overall_status":"Recruiting","enrollment":" Enrollment 131","initiation":"Initiation: 07/21/2023","start_date":" 07/21/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-05-03"}]